Low- Versus High-Dose Rituximab for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

OP0028 Efficacy of different doses of rituximab for the treatment of RA: Data from the cererra collaboration

(2014) K. Chatzidionysiou et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety of rituximab in rheumatoid arthritis: A long-term prospective single-center study of gammaglobulin concentrations and infections

(2012) Anne Isvy et al.   JOINT BONE SPINE

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

(2011) M. H. Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE

(2011) Paul P Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections

(2011) Daniel Tesfa et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

(2010) P. P. Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: Meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons

(2010) Niels Graudal et al.   ARTHRITIS AND RHEUMATISM

More or less rituximab? Biology and clinic, regulators and researchers

(2010) Ronald F. van Vollenhoven   ARTHRITIS AND RHEUMATISM

Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion

(2010) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

(2010) R. Conway et al.   RHEUMATOLOGY

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

(2010) A. Rubbert-Roth et al.   RHEUMATOLOGY

The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

(2010) Young Ho Lee et al.   RHEUMATOLOGY INTERNATIONAL

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate

(2010) William Rigby et al.   ARTHRITIS CARE & RESEARCH

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis

(2009) Nathan Vastesaeger et al.   RHEUMATOLOGY

Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis

(2008) D. McGonagle et al.   RHEUMATOLOGY